Praluent mechanism of action?

Praluent (evolocumab) mechanism of action:

- It is a human monoclonal antibody that binds to PCSK9.
- By binding PCSK9, it prevents PCSK9 from interacting with LDL receptors (LDLR) on hepatocytes.
- This stops PCSK9-mediated degradation of LDL receptors, so more LDL receptors are available on the liver surface.
- More LDL receptors mean increased hepatic uptake and clearance of LDL cholesterol from the blood, lowering circulating LDL-C (and often related lipids).

Clinically, this can lower LDL-C by roughly 50–60% when added to statin therapy.